Karyopharm Therapeutics Inc.

Biogen Ma Inc.

Archemix Corporation

Microdose Therapeutx, Inc.

Epix Pharmaceuticals, Inc.

Iveric Bio, Inc.

Dilara McCauley

Sharon Shacham

Sharon Shechter

Vincent Premaratna Sandanayaka

Erkan Baloglu

William Senapedis

Ori Kalid

Yosef Landesman

Gali Golan

Charles Wilson

Thomas Greene McCauley

David Epstein

James Rottman

Claude Benedict

Markus Kurz

Jeffrey C Kurz

Oren Becker

Ashis K Saha

Yael Marantz

Pini Orbach

Trinayan Kashyap

Zhaoda Zhang

Jian Lin

Xiang Y Yu

Vincent Jacques

Srinivasa Rao Cheruku

Silvia Noiman

Mercedes Lobera

Anurag Sharadendu

Nili Schutz

Efrat Ben-Zeev

A Sekar Reddy

Kimberley Gannon

Robert Christian Penland

Michael Xie

Victor J Cee

John Louis Diener

Brian Alan Lanman

Jennifer Elizabeth Golden

Roland W Burli

Susana C Neira

Michael Kauffman

Tami Rashal

Jean-Richard Saint-Martin

Jeffrey Kurz

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I.

Hydrazide containing nuclear transport modulators and uses thereof

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Nuclear transport modulators and uses thereof

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Aptamer therapeutics useful in the treatment of complement-related disorders

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of making and using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, hydrates, or solvates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using such compounds and compositions to treat various disorders associated with CRM1 activity.

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Growing community of inventors

Arlington, MA, United States of America

Dilara McCauley